A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

A Phase II Study of Adjuvant Chemotherapy of Tegafur–Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy

Published:2016-12-01 Issue:12 Volume:36 Page:6505-6510
ISSN:0250-7005
Container-title:Anticancer Research
language:
Short-container-title:AR

Author:

TANAKA SATORU,IWAMOTO MITSUHIKO,KIMURA KOSEI,TAKAHASHI YUKO,FUJIOKA HIYOYA,SATO NAYUKO,TERASAWA RISA,KAWAGUCHI KANAKO,IKARI AYANA,TOMINAGA TOMO,MAEZAWA SAKI,UMEZAKI NODOKA,MATSUDA JUNNA,UCHIYAMA KAZUHISA

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Link

http://ar.iiarjournals.org/content/36/12/6505.full.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment;Expert Review of Anticancer Therapy;2023-05-31

2. Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives;Cancer Treatment and Research;2023

3. A four‐gene signature predicts the efficacy of paclitaxel‐based neoadjuvant therapy in human epidermal growth factor receptor 2–negative breast cancer;Journal of Cellular Biochemistry;2018-12-05

4. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes;Annals of Surgical Oncology;2018-05-21

5. Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer;In Vivo;2018